Tekla Common Stock Total Equity from 2010 to 2026
| HQL Stock | USD 16.90 0.28 1.68% |
Common Stock Total Equity | First Reported 2010-12-31 | Previous Quarter 274.7 K | Current Value 260.9 K | Quarterly Volatility 144.6 M |
Check Tekla Life financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tekla Life's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 0.0 or Total Revenue of 104.3 M, as well as many indicators such as Price To Sales Ratio of 4.43, Dividend Yield of 0.13 or PTB Ratio of 0.82. Tekla financial statements analysis is a perfect complement when working with Tekla Life Valuation or Volatility modules.
Tekla | Common Stock Total Equity | Build AI portfolio with Tekla Stock |
Historical Common Stock Total Equity data for Tekla Life serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Tekla Life Sciences represents a compelling investment opportunity.
Latest Tekla Life's Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Tekla Life Sciences over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Tekla Life's Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Life's overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Tekla Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 134,248,993 | |
| Geometric Mean | 9,276,191 | |
| Coefficient Of Variation | 107.73 | |
| Mean Deviation | 132,443,807 | |
| Median | 80,500,000 | |
| Standard Deviation | 144,626,346 | |
| Sample Variance | 20916.8T | |
| Range | 345.1M | |
| R-Value | (0.62) | |
| Mean Square Error | 13683.8T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | (17,809,691) | |
| Total Sum of Squares | 334668.5T |
Tekla Common Stock Total Equity History
About Tekla Life Financial Statements
Tekla Life investors utilize fundamental indicators, such as Common Stock Total Equity, to predict how Tekla Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 274.7 K | 260.9 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Tekla Life Correlation against competitors. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. Market participants price Tekla higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tekla Life assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 2.594 | Dividend Share 1.82 | Earnings Share 2.79 | Revenue Per Share | Quarterly Revenue Growth (0.70) |
Tekla Life Sciences's market price often diverges from its book value, the accounting figure shown on Tekla's balance sheet. Smart investors calculate Tekla Life's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Tekla Life's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.